| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1031657533 |
| P356 | DOI | 10.2165/00003495-200767140-00003 |
| P8608 | Fatcat ID | release_s5lcg6v3mncftgek6bjicrtoca |
| P698 | PubMed publication ID | 17883284 |
| P2093 | author name string | Dennis Andress | |
| P2860 | cites work | Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis | Q82915984 |
| Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients | Q83842497 | ||
| Resurrection of vitamin D deficiency and rickets | Q24685737 | ||
| Vitamin D. | Q27919675 | ||
| Phosphate regulation of vascular smooth muscle cell calcification | Q28139908 | ||
| Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction | Q28213597 | ||
| Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation | Q28240596 | ||
| Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization | Q28283679 | ||
| Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein | Q28304798 | ||
| 1,25-Dihydroxyvitamin D3 stimulates the synthesis of matrix gamma-carboxyglutamic acid protein by osteosarcoma cells. Mutually exclusive expression of vitamin K-dependent bone proteins by clonal osteoblastic cell lines | Q28567649 | ||
| Vitamin D(3) analogs (MC 1288, KH 1060, EB 1089, GS 1558, and CB 1093): studies on their mechanism of action. | Q31943140 | ||
| Pathogenesis of secondary hyperparathyroidism | Q33816189 | ||
| Vascular smooth muscle cell proliferation in the pathogenesis of atherosclerotic cardiovascular diseases | Q33917594 | ||
| TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. | Q34145009 | ||
| 1,25-dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells | Q34264285 | ||
| Vitamin D analogues for the management of secondary hyperparathyroidism. | Q34426252 | ||
| Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries | Q34574684 | ||
| Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy | Q34648670 | ||
| C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients | Q34766550 | ||
| 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system | Q34793842 | ||
| Regulation of 1,25-dihydroxyvitamin D3 receptor gene expression by 1,25-dihydroxyvitamin D3 in the parathyroid in vivo | Q35817684 | ||
| Vascular calcification mechanisms | Q35972974 | ||
| Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs? | Q36091641 | ||
| Vitamin D treatment in chronic kidney disease | Q36216940 | ||
| Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation | Q36351694 | ||
| Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo | Q36371196 | ||
| Secondary hyperparathyroidism in chronic kidney disease: focus on clinical consequences and vitamin D therapies | Q36567144 | ||
| Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies | Q36947025 | ||
| Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells | Q37692403 | ||
| 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter | Q38291080 | ||
| Critical roles of a cyclic AMP responsive element and an E-box in regulation of mouse renin gene expression. | Q38296694 | ||
| High-density lipoprotein regulates calcification of vascular cells. | Q39265314 | ||
| Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog | Q39610821 | ||
| Bone morphogenetic protein expression in human atherosclerotic lesions. | Q40304303 | ||
| Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study | Q40403628 | ||
| Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. | Q40509707 | ||
| 1alpha,25-dihydroxyvitamin D(3) and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL. | Q40907003 | ||
| Inhibition of growth by calcitriol in a proximal tubular cell line (OK). | Q41504441 | ||
| Differential effects of vitamin D analogs on vascular calcification | Q42163977 | ||
| Effects of 1,25(OH)2D3 on compensatory renal growth in the growing rat. | Q42473943 | ||
| Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats | Q42542097 | ||
| Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality | Q43546639 | ||
| Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? | Q43890118 | ||
| Vitamin D analogue-specific recruitment of vitamin D receptor coactivators | Q43991826 | ||
| Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats | Q44137817 | ||
| Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells | Q44173368 | ||
| Long-term effect of 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in haemodialysis patients. One-year administration study | Q44184093 | ||
| A comparison between 1,25-dihydroxy-22-oxavitamin D(3) and 1,25-dihydroxyvitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action. | Q44184100 | ||
| Different effects of 22-oxacalcitriol and calcitriol on the course of experimental chronic renal failure | Q44186291 | ||
| Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? | Q44231254 | ||
| Differential effect of vitamin D analogues on the proliferation of vascular smooth muscle cells | Q44461009 | ||
| In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3. | Q44560713 | ||
| Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification in hemodialysis patients | Q44939233 | ||
| Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice | Q44942856 | ||
| Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems | Q45059018 | ||
| Production of plasminogen activator inhibitor-1 (PAI-1) by endothelial cells: differential responses to calcitriol and paricalcitol | Q45197182 | ||
| Atherosclerosis and vascular calcification are independent predictors of left ventricular hypertrophy in chronic haemodialysis patients | Q45269825 | ||
| Activated injectable vitamin D and hemodialysis survival: a historical cohort study | Q45281077 | ||
| Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients | Q46122319 | ||
| The mechanisms of uremic serum-induced expression of bone matrix proteins in bovine vascular smooth muscle cells | Q46281459 | ||
| Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells | Q46646123 | ||
| Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients | Q46724855 | ||
| Differential effects of Vitamin D analogs on bone formation and resorption | Q46768716 | ||
| Antiproteinuric effect of oral paricalcitol in chronic kidney disease | Q46826570 | ||
| Relation of proximal aorta stiffness to left ventricular diastolic function in patients with end-stage renal disease | Q48596489 | ||
| Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. | Q50614739 | ||
| Differential effects of Vitamin D analogs on calcium transport. | Q53586618 | ||
| Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification. | Q53599962 | ||
| 1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. | Q54612212 | ||
| Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group | Q57223695 | ||
| Modulation of bone morphogenetic protein-2 and bone morphogenetic protein-4 gene expression in osteoblastic cell lines | Q61961247 | ||
| Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. | Q64913104 | ||
| Actions of 1,25-Dihydroxyvitamin D3 on Human Mesangial Cells | Q68251664 | ||
| Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients | Q71249215 | ||
| A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism | Q71612685 | ||
| Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway | Q73209080 | ||
| 22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis | Q73265430 | ||
| Increased biological potency of hexafluorinated analogs of 1,25-dihydroxyvitamin D3 on bovine parathyroid cells | Q73327385 | ||
| Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure | Q73446467 | ||
| Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease | Q73494695 | ||
| Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease | Q74756562 | ||
| Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study | Q77309259 | ||
| Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation | Q77357987 | ||
| Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats | Q77530599 | ||
| Comparative effect of oral pulse and intravenous calcitriol treatment in hemodialysis patients: the effect on serum IL-1 and IL-6 levels and bone mineral density | Q77570501 | ||
| Calcitriol modulates in vivo and in vitro cytokine production: a role for intracellular calcium | Q77650607 | ||
| Fibronectin and collagen I matrixes promote calcification of vascular cells in vitro, whereas collagen IV matrix is inhibitory | Q77666189 | ||
| A vitamin D analog regulates mesangial cell smooth muscle phenotypes in a transforming growth factor-beta type II receptor-mediated manner | Q78010405 | ||
| Inflammation enhances cardiovascular risk and mortality in hemodialysis patients | Q78163875 | ||
| Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure | Q78197798 | ||
| Expression of mRNAs for type-I collagen, bone sialoprotein, osteocalcin, and osteopontin at different stages of osteoblastic differentiation and their regulation by 1,25 dihydroxyvitamin D3 | Q78200535 | ||
| Mortality risk among hemodialysis patients receiving different vitamin D analogs | Q79190034 | ||
| Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy | Q79326178 | ||
| Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease | Q79337877 | ||
| Potential role of active vitamin D in retarding the progression of chronic kidney disease | Q79377306 | ||
| Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency | Q79485416 | ||
| Use of genetically modified mice to examine the skeletal anabolic activity of vitamin D | Q79664829 | ||
| Differential effects of vitamin D receptor activators on vascular calcification in uremic rats | Q80540597 | ||
| P433 | issue | 14 | |
| P921 | main subject | vitamin D | Q175621 |
| P304 | page(s) | 1999-2012 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease | |
| P478 | volume | 67 |
| Q35959075 | Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature |
| Q37459100 | Ageing and vitamin D deficiency: effects on calcium homeostasis and considerations for vitamin D supplementation |
| Q33610354 | Association between vitamin D deficiency and health-related quality of life in patients with chronic kidney disease from the KNOW-CKD study |
| Q90185251 | BENEFICIAL EFFECTS OF PARICALCITOL ON CARDIAC DYSFUNCTION AND REMODELLING IN A MODEL OF ESTABLISHED HEART FAILURE |
| Q51478902 | Calcific uremic arteriolopathy treated with cinacalcet, paricalcitol, and autologous growth factors. |
| Q37310824 | Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift? |
| Q51731200 | Calcitriol Prevents Cardiovascular Repercussions in Puromycin Aminonucleoside-Induced Nephrotic Syndrome. |
| Q28258849 | Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy |
| Q50457562 | Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism. |
| Q38187107 | Drug adherence in chronic kidney diseases and dialysis |
| Q48614157 | Inhibitor effect of paricalcitol in rat model of pentylenetetrazol-induced seizures. |
| Q47133604 | Long-Term Therapy Outcomes When Treating Chronic Kidney Disease Patients with Paricalcitol in German and Austrian Clinical Practice (TOP Study). |
| Q37843788 | Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes |
| Q36684252 | Paricalcitol attenuates lipopolysaccharide-induced myocardial inflammation by regulating the NF-κB signaling pathway. |
| Q98778879 | Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis |
| Q37553481 | Selective vitamin D receptor activation as anti-inflammatory target in chronic kidney disease. |
| Q37842680 | Shining D' light on chronic kidney disease: mechanisms that may underpin the cardiovascular benefit of vitamin D. |
| Q38012025 | The immunoregulatory function of vitamin D: implications in chronic kidney disease |
| Q36613869 | The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection |
| Q33517923 | The role of 25-hydroxyvitamin D deficiency in promoting insulin resistance and inflammation in patients with chronic kidney disease: a randomised controlled trial |
| Q35573698 | The use of vitamin D analogues in chronic kidney diseases: possible mechanisms beyond bone and mineral metabolism |
| Q53314344 | The vitamin D system: a crosstalk between the heart and kidney. |
| Q90672687 | Vitamin D in Neurological Diseases: A Rationale for a Pathogenic Impact |
| Q35898186 | Vitamin D levels predict all-cause and cardiovascular disease mortality in subjects with the metabolic syndrome: the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study |
| Q36947025 | Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies |
Search more.